Farther Finance Advisors LLC Has $261,000 Stake in Axon Enterprise, Inc (NASDAQ:AXON)

Farther Finance Advisors LLC decreased its position in Axon Enterprise, Inc (NASDAQ:AXON) by 66.8% in the first quarter, according to its most recent 13F filing with the SEC. The firm owned 483 shares of the biotechnology company’s stock after selling 973 shares during the period. Farther Finance Advisors LLC’s holdings in Axon Enterprise were worth $261,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Fourth Dimension Wealth LLC acquired a new position in Axon Enterprise in the 4th quarter worth approximately $30,000. Elequin Capital LP acquired a new position in Axon Enterprise in the 4th quarter worth approximately $46,000. CoreFirst Bank & Trust acquired a new position in Axon Enterprise in the 4th quarter worth approximately $59,000. Global Financial Private Client LLC boosted its stake in Axon Enterprise by 11,100.0% in the 1st quarter. Global Financial Private Client LLC now owns 112 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 111 shares during the period. Finally, Prestige Wealth Management Group LLC boosted its stake in Axon Enterprise by 59.8% in the 4th quarter. Prestige Wealth Management Group LLC now owns 131 shares of the biotechnology company’s stock worth $78,000 after purchasing an additional 49 shares during the period. Institutional investors and hedge funds own 79.08% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on AXON shares. The Goldman Sachs Group lifted their target price on shares of Axon Enterprise from $730.00 to $830.00 and gave the company a “buy” rating in a research note on Wednesday, May 14th. Needham & Company LLC lifted their price objective on shares of Axon Enterprise from $600.00 to $750.00 and gave the company a “buy” rating in a research note on Thursday, May 8th. Northcoast Research lowered shares of Axon Enterprise from a “buy” rating to a “neutral” rating in a research note on Wednesday, February 19th. Barclays lifted their price objective on shares of Axon Enterprise from $726.00 to $735.00 and gave the company an “overweight” rating in a research note on Friday, May 9th. Finally, Bank of America boosted their target price on shares of Axon Enterprise from $750.00 to $895.00 and gave the stock a “buy” rating in a research report on Wednesday, June 4th. One analyst has rated the stock with a sell rating, one has given a hold rating and ten have given a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $699.55.

Axon Enterprise Stock Performance

NASDAQ:AXON opened at $770.79 on Thursday. Axon Enterprise, Inc has a 12-month low of $279.02 and a 12-month high of $806.64. The company has a quick ratio of 2.62, a current ratio of 2.83 and a debt-to-equity ratio of 0.68. The firm has a market capitalization of $60.01 billion, a PE ratio of 186.18, a price-to-earnings-growth ratio of 89.50 and a beta of 1.29. The firm has a 50-day moving average price of $683.57 and a 200 day moving average price of $624.47.

Axon Enterprise (NASDAQ:AXON) last posted its quarterly earnings results on Wednesday, May 7th. The biotechnology company reported $1.41 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.34 by $0.07. Axon Enterprise had a net margin of 14.86% and a return on equity of 5.81%. The firm had revenue of $603.63 million during the quarter, compared to analyst estimates of $585.67 million. During the same quarter in the prior year, the business posted $1.15 earnings per share. The company’s quarterly revenue was up 31.3% compared to the same quarter last year. Research analysts anticipate that Axon Enterprise, Inc will post 5.8 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, CEO Patrick W. Smith sold 10,000 shares of the firm’s stock in a transaction that occurred on Monday, April 21st. The shares were sold at an average price of $540.99, for a total transaction of $5,409,900.00. Following the completion of the sale, the chief executive officer now owns 3,063,982 shares of the company’s stock, valued at approximately $1,657,583,622.18. This trade represents a 0.33% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, President Joshua Isner sold 905 shares of the firm’s stock in a transaction that occurred on Tuesday, June 17th. The stock was sold at an average price of $776.39, for a total transaction of $702,632.95. Following the sale, the president now directly owns 268,735 shares of the company’s stock, valued at approximately $208,643,166.65. The trade was a 0.34% decrease in their position. The disclosure for this sale can be found here. Insiders sold 44,642 shares of company stock valued at $30,500,428 over the last quarter. Corporate insiders own 4.40% of the company’s stock.

About Axon Enterprise

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.